This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 Nov;17(11):e485.

doi: 10.1016/S1470-2045(16)30511-3. Epub 2016 Oct 20.

Sunitinib as adjuvant therapy for renal cell carcinoma

PMID: 27773485
DOI: 10.1016/S1470-2045(16)30511-3

Sunitinib as adjuvant therapy for renal cell carcinoma

Holly Baker. Lancet Oncol. 2016 Nov.

. 2016 Nov;17(11):e485.

doi: 10.1016/S1470-2045(16)30511-3. Epub 2016 Oct 20.

Author

PMID: 27773485
DOI: 10.1016/S1470-2045(16)30511-3

No abstract available

PubMed Disclaimer

Similar articles

Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T, Wong R, Davis ID. Nicholaou T, et al. Lancet. 2007 Jun 9;369(9577):1923-4. doi: 10.1016/S0140-6736(07)60903-9. Lancet. 2007. PMID: 17560435 No abstract available.
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M. Motzer RJ, et al. Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28. Eur Urol. 2018. PMID: 28967554 Free PMC article. Clinical Trial.
Pazopanib outscores sunitinib on tolerability.
[No authors listed] [No authors listed] Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19. Cancer Discov. 2014. PMID: 24402960
Sunitinib malate for the treatment of renal cell carcinoma.
Wood L. Wood L. Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Expert Opin Pharmacother. 2012. PMID: 22607009 Review.
Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C, Szczylik C. Porta C, et al. Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Cancer Treat Rev. 2009. PMID: 19249157 Review.

See all similar articles

Cited by

Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma.
Wu J, Jin S, Gu W, Wan F, Zhang H, Shi G, Qu Y, Ye D. Wu J, et al. Front Oncol. 2019 Mar 19;9:152. doi: 10.3389/fonc.2019.00152. eCollection 2019. Front Oncol. 2019. PMID: 30941304 Free PMC article.
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM. Jilaveanu LB, et al. Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066509 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information